Corporate Leadership Challenges - Compassionate Use & Expanded Access




“If you only have a limited number of doses of an experimental medicine, what do you do with that?  Do you make it available for expanded access or do you gain more data for your ultimate drug approval?”– Kenneth Moch. Kenneth I. Moch is the former President & CEO of Chimerix, Inc., an antiviral therapeutics company. In March/ April 2014, Ken guided Chimerix through a media firestorm around compassionate use of an early-stage developmental drug. Andrea Charles...
TO READ THE FULL STORY